Top Clinical Trials companies in Canada by Total Assets

This ranking features the top 30 Clinical Trials companies in Canada ranked by Total Assets, totaling a Total Assets of USD 32.17 B, for July 05, 2025.

#	Name	Market Capitalization Share Price Year-To-Date (YTD) return Price to Earnings Ratio (P/E) Revenue Revenue Year-on-Year (YoY) growth Operating Income EBIT EBITDA Free Cash Flow Dividend Yield Free Cash Flow Yield Total Liabilities Cash and Short-Term Investments	Stock Price	Change	Price (30 days)	52W low/high	Sector

Items per page

Frequently Asked Questions

Which Clinical Trials company in Canada has the highest Total Assets ?

The Clinical Trials company in Canada with the highest Total Assets is Bausch Health Companies Inc. (Toronto Stock Exchange: BHC.TO) at USD 26.52 B.

Which Clinical Trials company in Canada has the lowest Total Assets ?

The Clinical Trials company in Canada with the lowest Total Assets is Mind Medicine (MindMed) Inc. (NasdaqGS: MNMD) at None.

What are the top 10 Clinical Trials companies in Canada by Total Assets ?

The top 10 Clinical Trials companies in Canada by Total Assets are Bausch Health Companies Inc., AbCellera Biologics Inc., Xenon Pharmaceuticals Inc., Knight Therapeutics Inc., Aurora Cannabis Inc., Aurinia Pharmaceuticals Inc., Zymeworks Inc., enGene Holdings Inc. Common Stock, Repare Therapeutics Inc. and Medexus Pharmaceuticals Inc..

What are the bottom 10 Clinical Trials companies in Canada by Total Assets ?

The bottom 10 Clinical Trials companies in Canada by Total Assets are Mind Medicine (MindMed) Inc., ESSA Pharma Inc., Milestone Pharmaceuticals Inc., Eupraxia Pharmaceuticals Inc., Edesa Biotech, Inc., Aptose Biosciences Inc., BriaCell Therapeutics Corp., Cardiol Therapeutics Inc., Firefly Neuroscience, Inc. and NervGen Pharma Corp..